Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Stephanie McNally

Menopause · Northwell Health

View

Dr. Mercedes Castiel

Menopause · The Cancer Care Concierge LLC

View

Dr. Megan Evans

Menopause · Tufts

View

Dr. Karen Adams

Menopause · Stanford

View

Dr. Susan Khalil

MIGS · ISMMS

View

Dr. Tori O’Daniel

OB Hospitalist · Laborie-MCH division, Senior Medical Director

View

Dr. Alissa Erogbogbo

OB Hospitalist · Washington Health System

View

Dr. Christina Adams

OB Hospitalist · Flagler Hospital

View

Dr. Brigid McCue

OB Hospitalist · Northwell Health

View

Dr. Bruce Bekkar

General OBGYN · ecoAmerica

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    RKDr. Risa Kagan
    Leading Voice

    Dr. Risa Kagan

    Obstetrics & Gynecology (OBGYN) · Menopause
    Sutter Health
    drrisakagan
    Berkeley, CA

    Research

    Response to: Letter to the Editor Regarding: Safety of Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies.

    2025

    Via Advances in Therapy

    Research

    Major adverse cardiovascular events risk in menopausal women treated with oral estradiol/micronized progesterone versus conjugated estrogens/medroxyprogesterone: a claims data analysis in the USA.

    2025

    Via Climacteric

    Research

    Oral lasofoxifene's effects on moderate to severe vaginal atrophy in postmenopausal women: two phase 3, randomized, controlled trials.

    2024

    Via Menopause

    Research

    Symptoms of menopause.

    2024

    Via Menopause

    Research

    Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies.

    2024

    Via Advances in Therapy

    Research

    Oral estradiol/micronized progesterone may be associated with lower risk of venous thromboembolism compared with conjugated equine estrogens/medroxyprogesterone acetate in real-world practice.

    2023

    Via Maturitas

    Research

    Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.

    2023

    Via Menopause

    Research

    Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptoms.

    2022

    Via Menopause

    Research

    Hormone therapy for postmenopausal osteoporosis management.

    2021

    Via Climacteric

    Research

    Impact of sleep disturbances on employment and work productivity among midlife women in the US SWAN database: a brief report.

    2021

    Via Menopause

    Research

    Uterine bleeding with hormone therapies in menopausal women: a systematic review.

    2020

    Via Climacteric

    Research

    Efficacy and safety of erenumab in women with a history of menstrual migraine.

    2020

    Via The Journal of Headache and Pain

    Research

    TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women.

    2019

    Via Climacteric

    Research

    Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.

    2019

    Via Menopause

    Research

    Practical Treatment Considerations in the Management of Genitourinary Syndrome of Menopause.

    2019

    Via Drugs & Aging